Saturday 17 October 2026
Export CELU’s income statement to Excel — free account
Celularity, Inc.
CELU Healthcare Biotechnology
Celularity, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $26.6 million, down 51.0% from fiscal 2024. In the quarter to March 2026, revenue fell 66.3%, EPS grew 103.6%, free cash flow grew 148.4% and total debt fell 4.73%, each against the same quarter a year earlier.
1.25
0.08
−6.02%
Follow CELU
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | 97.00 | 93.00 | 43.90 | 10.49 | 1.59 | 1.30 | 1.00 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | 100.10 | 121.70 | 134.00 | 131.86 | 13.40 | 7.97 | 4.35 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | 225 | 225 | 120 | 123 | 115 | ||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.09 | 0.08 | 0.19 | 0.44 | 0.23 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | 14 | 21 | 18 | 23 | 54 | 27 | ||||
| Gross margin, % | — | — | — | — | 65.46 | 54.76 | (9.40) | 29.66 | 72.36 | 24.39 | |||||
| EBT | — | — | 0 | 7 | (213) | (100) | 14 | (196) | (58) | (92) | |||||
| EBT margin, % | — | — | 0.00 | 0.00 | (1,491.34) | (469.17) | 79.03 | (862.00) | (106.77) | (345.44) | |||||
| Net income | — | 0 | 0 | 6 | (208) | (100) | 14 | (196) | (58) | (92) | |||||
| Depreciation | — | — | — | — | 138 | 9 | 13 | 122 | 8 | 7 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | 0.00 | 0.00 | 7.75 | 3.18 | 1.28 | 1.28 | 2.48 | 1.04 | ||||
| Earnings | — | — | 0.00 | 6.47 | (113.06) | (14.90) | 1.00 | (11.02) | (2.64) | (3.47) | |||||
| Cash flow | — | — | 0.00 | (1.21) | (34.31) | (16.42) | (9.85) | (2.17) | (0.29) | (0.52) | |||||
| Capex | — | — | 0.00 | 0.00 | (15.11) | (0.92) | (0.37) | (0.06) | (0.01) | 0.00 | |||||
| Free cash flow | — | — | 0.00 | (1.21) | (49.42) | (17.34) | (10.23) | (2.23) | (0.30) | (0.52) | |||||
| Book value | — | — | 0.03 | 5.50 | 10.16 | 14.83 | 14.22 | 2.30 | 0.40 | (1.49) | |||||
| Shares, m | — | — | 1 | 1 | 2 | 7 | 14 | 18 | 22 | 26 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | 0.00 | 0.00 | 11.45 | 0.00 | 0.00 | 0.00 | ||||
| P/S | — | — | — | — | 0.00 | 16.09 | 8.80 | 2.19 | 0.84 | 1.07 | |||||
| P/B | — | — | — | — | 0.00 | 3.45 | 0.79 | 1.22 | 5.15 | 0.00 | |||||
| EV/Sales | — | — | — | — | 0.00 | 15.81 | 11.67 | 5.05 | 1.61 | 2.64 | |||||
| EV/FCF | — | — | — | — | (2.78) | (2.90) | (1.47) | (2.89) | (13.27) | (5.22) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | 0 | (1) | (63) | (110) | (138) | (39) | (6) | (13) | ||||
| Capex | — | — | — | — | (28) | (6) | (5) | (1) | 0 | — | |||||
| Free cash flow | — | — | 0 | (1) | (91) | (116) | (143) | (40) | (7) | (13) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | 0 | 1 | 45 | 33 | (29) | (48) | (33) | (68) | ||||
| Total debt | — | — | 0 | — | 31 | 31 | 66 | 39 | 42 | 48 | |||||
| Net debt | — | — | 0 | (1) | (24) | (6) | 52 | 39 | 42 | 42 | |||||
| Shareholders’ equity | — | — | 0 | 5 | 19 | 99 | 199 | 41 | 9 | (38) | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | (1.26) | 4.03 | (57.63) | (23.69) | 3.48 | (72.04) | (41.86) | (76.50) | ||||
| ROIC | — | — | (0.46) | (25.77) | 0.00 | (73.05) | (6.39) | (150.27) | (47.58) | (1,070.92) | |||||
| ROE | — | — | 0.00 | 234.03 | 79.12 | 46.35 | 9.51 | (163.67) | (232.51) | 628.23 | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Mar 2026 · fundamentals updated 1 Oct 2026
Charts ten years each
Celularity, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| SER Serina Therapeutics, Inc. | $45.5M | — (loss-making) | — (loss-making) | +2,500.00% (above 0%: growing) | n/m | −76.82% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| ANVS Annovis Bio, Inc. | $44.8M | — (loss-making) | — | — | n/m | −329.18% (below 0%: shrinking) | — | 0.00% | Compare |
| ALDX Aldeyra Therapeutics, Inc. | $44.5M | — (loss-making) | — | — | n/m | +46.09% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CELU Celularity, Inc. | $43.2M | — (loss-making) | — (loss-making) | −66.34% (below 0%: shrinking) | n/m | +148.35% (above 0%: growing) | 62.25% | (263.47%) | |
| DWTX Dogwood Therapeutics, Inc | $42.5M | — (loss-making) | — | — | n/m | +10.31% (above 0%: growing) | — | 0.00% | Compare |
| SGMOQ Sangamo Therapeutics, Inc. | $41.9M | — (loss-making) | — (loss-making) | −77.60% (below 0%: shrinking) | n/m | +26.21% (above 0%: growing) | 100.00% | (2,215.40%) | Compare |
| VERU Veru Inc. | $41.6M | — (loss-making) | — (loss-making) | +287.06% (above 0%: growing) | n/m | +0.27% (above 0%: growing) | 34.92% | 0.00% | Compare |
| TIL Instil Bio, Inc. | $41.6M | — (loss-making) | — | — | n/m | +68.62% (above 0%: growing) | 0.00% | 0.00% | Compare |
| GRCE Grace Therapeutics, Inc. | $41.0M | — (loss-making) | — (loss-making) | +5,127.27% (above 0%: growing) | n/m | −78.85% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $42.2M | — | — | +1,393.53% | — | +5.29% | 17.46% | 0.00% |
Celularity, Inc. (CELU) key facts
- Concern: Celularity, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $26.6 million, down 51.0% from fiscal 2024.
- Celularity, Inc. (CELU) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, CELU traded at $1.25, a market capitalization of $43.2 million.
- Return on equity was 628.2% and debt-to-equity -1.17.
- Its Piotroski F-score is 1 out of 9 and its Altman Z-score is −15.22 (distress zone) for fiscal 2025.